Network meta-analysis of 262 trials (99 791 adults with overweight or obesity, 19 drugs): versus lifestyle alone, tirzepatide (-14.9%) and CagriSema (-14.8%) gave most 1-year weight loss; larger benefits came with more harms and discontinuation. Few cut cardiovascular events.
Meta-analysisn = 99,791
Nong et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis